Modern Approaches to the Treatment of Castration-Resistant Prostate Cancer
Article Sidebar
Main Article Content
Abstract
In the treatment of metastatic hormone-resistant prostate cancer, the use of chemotherapy both in single mode and in combination with other drugs is currently the standard. In most cases, prostate cancer responds well to hormonal androgen deprivation therapy (therapeutic castration). Unfortunately, over time, in many patients, the tumor begins to progress, despite ongoing treatment. A decrease in testosterone levels becomes insufficient to keep the growth of malignant cells. This condition is called hormone-resistant, hormone-refractory, or castration-resistant prostate cancer. The search for drugs, their combinations and new treatment regimens for patients with GRP continues in order to improve treatment results.
Article Details
Section
How to Cite
References
Чиссов В. И., Русаков И. Г. Заболеваемость раком предстательной железы в Российской Федерации. Экспериментальная и клиническая урология. 2011. № 2-3. URL: http://www.ecuro.ru/ journal/nomer-2-3-2011.
Самойлик Б. М. Эпидемиологические аспекты рака предстательной железы в Краснодарском крае за период с 2000 по 2009 год. Материалы V Конгресса Российского общества онкоурологов. 2010. URL: http://www.roou.ru/.uploads/press/tezis/292/5_ Congress_Oncourology-inet27.fi le27.fi le.pdf
Енгалычев Ф. Ш., Миронов М. А., Галкина Н. Г., Лямкин С. В. Статистические данные по раку предстательной железы в Пензенской области за 2005-2009 годы. Материалы V Конгресса Российского общества онкоурологов. 2010. URL: http://www.roou. ru/.uploads/press/tezis/292/5_Congress_Oncourology-inet27.file27. fi le.pdf
Карякин О. Б. Современные подходы к лечению гормонрезистентного рака предстательной железы. Онкоурология. 2011. № 1. С.101-107.
Аполихин О. И., Катибов М. И.,Шадеркин И. А. Пути стандартизации оказания этапной помощи пациентам с раком предстательной железы в РФ. Экспериментальная и клиническая урология. 2011. № 2-3. URL: http://www.ecuro.ru/journal/nomer2-3-2011.
H eidenreich A., Bolla M., Joniau S., Kwast T. H., Matveev V., Mason M. D, Mottet N., Schmid H.-P., Wiegel T., Zattoni F. Рекомендации по лечению рака предстательной железы. Европейская ассоциация урологов. URL: http://www.uroweb.org/fi leadmin/ tx_eauguidelines/2009/Full/ru_3_Prostate_Cancer.pdf
T annok I. et al.; TAX 327 Investigators. Docetaxel plus prednisone or mi-toxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–1512. 23. D e Bono J. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364 , 1995–2005 (2011).
Fizazi K. et al. Final overall survival (OS) analysis of COU-AA301, a phase 3 study of Abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) pretreated with docetaxel. Presented at the European Multidisciplinary Cancer Congress ECCO. Stockholm, Sweden 23–27 September 2011. EJC Volume 47 Supplement 2, September 2011, LBA1. 25. F leming M. et al., Results of a randomized phase II study of mitoxantrone with cetuximab in metastatic castrate- resistant prostate cancer (CRPC) previously treated with docetaxel - based chemotherapy. Journal of Clinica l Oncology
Abstract number 4555 (2010). 26. B erger E. et al. Results of a randomized phase II study of irofl uven in hormone- refractory prostate cancer patients that have failed fi rst - line docetaxel treatment. American Society of Clinical Oncology Genitourinary Cancers Symposium. Abstract number: 5068. 2007.
R osenberg J. et al., Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer. 2007 Aug 1;110(3):556-63. 28. d e Bono J. et al., Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010 Oct 2;376(9747):1147-54. 29. T he Cochrane Handbook for Systematic Reviews of Interventions. Chapter 8:Assessing risk of bias in included studies. URL: http:// www.cochrane-handbook.org/
T annock I. et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone- resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14, 1756- 1764 (1996). 31. B erryW. et al. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol. 168 , 2439 - 2443 (2002).
Горяйнов С. В., Реброва О. Ю. Непрямые сравнения в оценке медицинских технологий// Медицинские технологии. Оценка и выбор. 2011. №3(5).С. 9-12. 33. Glenny A. et al., Indirect comparisons of competing interventions. Health Technol Assess. 2005 Jul;9(26):1-134, iii-iv. 34. B ucher H. et al., The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997 Jun;50(6): 683-91.
Fazliddinovna, M. G. . (2023). Oncopsychology of Patients with Breast Cancer after Treatment. Scholastic: Journal of Natural and Medical Education, 2(2), 111–116.
М.Р. Турдиев, Г.Ф. Махмудова. Морфофункциональные изменения, происходящие в селезенке в результате действия внешних и внутренних факторов// Тиббиётда янги кун» №11(49), 2022, 466-474.
Makhmudova Guljamol Fazliddinovna. (2023). Age- related factors in diagnosis of malignant neoplasms of the female genital area. IQRO JURNALI, 2(2), 675–682.
Нурбобоев Адхамбек Уйгунович, Махмудова Гулжамол Фазлиддиновна. (2023). Возрастные особенности в диагностики опухолей молочной железы. IQRO JURNALI, 2(2), 683–688.
Makhmudova Guljamol Fazliddinovna, Nurboboyev Adkhambek Uygunovich. (2023). Comparison of the results of morphological changes observed in the spleen under the influence of carcinogens in the experiment. IQRO JURNALI, 2(1), 273–278
NA Uygunovich, MG Fazliddinovna, SZ Rakhmonovna. Laparoscopic Methods in the Diagnosis and Treatment of Emergency Surgical Diseases of the Abdominal Cavity // European Multidisciplinary Journal of Modern Science//-2022.- 4, 196-202.
G. F., M. ., & F. Sh., X. . (2022). Pathomorphological Changes Occurring in the Spleen as a Result of External and Internal Factors. INTERNATIONAL JOURNAL OF HEALTH SYSTEMS AND MEDICAL SCIENCES, 1(5), 132–137.
Fazliddinovna, M. G. . (2023). Oncopsychology of Patients with Breast Cancer after Treatment. Scholastic: Journal of Natural and Medical Education, 2(2), 111–116.
Ягудина Р. И., Куликов А. Ю., Аринина Е. Е. Фармакоэкономика в онкологии. М.: Издательство «Шико», 2011. 424 с.: ил. 36. Oudard S. TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. Future Oncol. 2011 Apr;7(4):497-506.